Lisavanbulin is a Small Molecule owned by Basilea Pharmaceutica, and is involved in 3 clinical trials, which were completed.

Lisavanbulin (BAL-101553) is a tubulin inhibitor. Administration of BAL101553 and conversion into the active form BAL27862, this agent binds to tubulin at a site distinct from the vinca-alkaloid-binding site, and prevents tubulin polymerization and destabilizes microtubules ultimately leading to cell cycle arrest, blockage of cell division and an induction of cell death in cancer cells.

The revenue for Lisavanbulin is expected to reach a total of $547m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Lisavanbulin NPV Report.

Lisavanbulin is originated and owned by Basilea Pharmaceutica.

Lisavanbulin Overview

Lisavanbulin (BAL-101553) is under development for the treatment of advanced or recurrent solid tumors including colorectal cancer, gastric or cancers of the gastro-esophageal junction, non-small cell lung cancer, ovarian cancer, pancreatic cancer (including ampullary), triple-negative breast cancer, fallopian tube cancer, primary peritoneal cancer, endometrial cancer, malignant glioma and recurrent glioblastoma multiforme. It is administered through oral and intravenous routes. BAL101553 is a highly water soluble lysine prodrug of the synthetic small molecule BAL27862. It is a small molecule drug with a dual mode of action, targeting intracellular microtubules and in addition blocking the tumor blood supply.

It was also under development for the treatment of glioblastoma multiforme.

Basilea Pharmaceutica Overview

Basilea Pharmaceutica (Basilea) is a biopharmaceutical company that develops and markets antibiotics, antifungals and oncology drugs. The company products are for increasing resistance and non-response to present treatment options for various therapeutic areas such as cancer, bacterial infections and fungal infections. Basilea also conducts research in the areas of anti-infectives, cancer and bacterial or fungal strains. It discovers drugs with the help of various technologies such as genomics, assay development, cell biology and others. The company also operates in France, the UK, China, Germany, Spain, Switzerland, Italy and Denmark. Basilea is headquartered in Basel, Switzerland.

The company reported revenues of (Swiss Francs) CHF148.1 million for the fiscal year ended December 2021 (FY2021), an increase of 16.1% over FY2020. The operating profit of the company was CHF0.7 million in FY2021, compared to an operating loss of CHF8.5 million in FY2020. The net loss of the company was CHF6.8 million in FY2021, compared to a net loss of CHF14.7 million in FY2020.

Quick View – Lisavanbulin

Report Segments
  • Innovator
Drug Name
  • Lisavanbulin
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.